1. ALLA AKTIER
  2. NYHETER
  3. DICOT PHARMA

Dicot Pharma

Nyheter Dicot Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27

Uppsala, Sweden, May 22, 2026. Dicot Pharma invites shareholders and other investors to a live company presentation and Q&A session in connection with the company’s ongoing rights offering. The company will present its plans for phase 2b, upcoming milestones, and how to participate in the offering. The presentation will take place via Zoom on May 27 at 12:00 p.m. CEST.

The presentation is open to everyone. To register to attend, please go to https://us02web.zoom.us/webinar/register/WN_mqkLMrccTBOpP9oFIQdvBA. If you can’t make it at the scheduled time, you’ll be able to watch the presentation later.

Please feel free to send any questions you may have before the presentation to info@dicotpharma.com.

The broadcast will be moderated by Alexander Kangas from Corpura, and participants from the company will include CEO Elin Trampe and CFO Björn Petersson. Note that the presentation will be in Swedish.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.

Attachments
Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27

Datum 2026-05-22, kl 09:45
Källa MFN
Bifogade filer
Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27